Clinical Data said it plans to offer the 454 GS FLX ‘Next Generation’ sequencing technology as a fee-for-service offering to clients worldwide and has said it will collaborate with Roche to co-market the service.
“The Genome Sequencer FLX represents the most advanced state-of-the-art, high throughput and cost-effective sequencing technology to support the expectations and needs of our customers’ research,” stated Robert Bondaryk, senior vice president and general manager of Cogenics, a division of Clinical Data.
Financial terms of the deal were not disclosed.